FAK tyrosine 407 organized with integrin αVβ5 in Hs578Ts(i)8 advanced triple-negative breast cancer cells

Payan,Iliet; McDonnell,Susan; Torres,Haydee  M.; Steelant,Wim  F.A.; Van Slambrouck,Séverine

doi:10.3892/ijo.2016.3422

FAK tyrosine 407 organized with integrin αVβ5 in Hs578Ts(i)8 advanced triple-negative breast cancer cells

Authors:
- Iliet Payan
- Susan McDonnell
- Haydee M. Torres
- Wim F.A. Steelant
- Séverine Van Slambrouck
View Affiliations

Affiliations: School of Science, Technology and Engineering Management, St. Thomas University, Miami Gardens, FL 33054, USA, UCD School of Chemical and Bioprocess Engineering, University College Dublin, Belfield Dublin 4, Ireland, Department of Chemistry and Biochemistry, South Dakota State University, Brookings, SD 57007, USA
Published online on: March 7, 2016 https://doi.org/10.3892/ijo.2016.3422
Pages: 2043-2054

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase known to promote cell migration and invasiveness. Overexpression and increased activity of FAK are closely associated with metastatic breast tumors and are linked to poor prognosis. This study discovered an inverse correlation between FAK activity and migratory and invasive behavior. We show decreased phosphorylation levels of FAK at tyrosine residues 397 and 861, and most prominently at Y407, in the more invasive Hs578Ts(i)8 subclone of the Hs578T breast cancer progression model. There is limited information available on FAK Y407, and here we demonstrate its presence in triple-negative breast cancer (TNBC) cell lines. Furthermore, our studies propose that localization of FAK Y407, rather than FAK expression and overall FAK Y407 phosphorylation levels, is crucial for the control of cell motility. FAK Y407 is found extensively at the cell periphery in focal adhesion-like structures at each end of actin stress fibers and organized with integrin αVβ5 receptors, linking the αVβ5 integrin-mediated migratory behavior of Hs578Ts(i)8 cells to FAK Y407. These data suggest that subcellular localization, next to expression and activity levels, are important for understanding TNBC progression. Such an approach opens new avenues for further studies and may provide novel insight for the classification of TNBC and facilitate the discovery of effective biomarkers for diagnosis and therapy of TNBC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	American Cancer Society. Breast Cancer Facts and Figures. 2015, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015. Accessed: February 9, 2016
3	BreastCancer.org. US Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed: February 9, 2016
4	Kimbung S, Loman N and Hedenfalk I: Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 35:85–95. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zardavas D, Irrthum A, Swanton C and Piccart M: Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 12:381–394. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
7	Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R and Symmans WF: Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 28:913–920. 2015. View Article : Google Scholar : PubMed/NCBI
8	Xu H, Eirew P, Mullaly SC and Aparicio S: The omics of triple-negative breast cancers. Clin Chem. 60:122–133. 2014. View Article : Google Scholar
9	Lee JM, Ledermann JA and Kohn EC: PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar :
10	Bayraktar S and Glück S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar : PubMed/NCBI
11	Brewster AM, Chavez-MacGregor M and Brown P: Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 15:e625–e634. 2014. View Article : Google Scholar : PubMed/NCBI
12	Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, et al: TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
13	Anbalagan M, Moroz K, Ali A, Carrier L, Glodowski S and Rowan BG: Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer. PLoS One. 7:e330172012. View Article : Google Scholar : PubMed/NCBI
14	Chavez KJ, Garimella SV and Lipkowitz S: Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32:35–48. 2010.
15	Hughes L, Malone C, Chumsri S, Burger AM and McDonnell S: Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis. 25:549–557. 2008. View Article : Google Scholar : PubMed/NCBI
16	Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM and Ueno NT: Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 6:12890–12908. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sulzmaier FJ, Jean C and Schlaepfer DD: FAK in cancer: Mechanistic findings and clinical applications. Nat Rev Cancer. 14:598–610. 2014. View Article : Google Scholar : PubMed/NCBI
18	Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, et al: High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype. BMC Cancer. 14:769–777. 2014. View Article : Google Scholar : PubMed/NCBI
19	Nakamura K, Yano H, Schaefer E and Sabe H: Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: Analysis of specific phosphorylation events using site-directed antibodies. Oncogene. 20:2626–2635. 2001. View Article : Google Scholar : PubMed/NCBI
20	Le Boeuf F, Houle F and Huot J: Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem. 279:39175–39185. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lim Y, Park H, Jeon J, Han I, Kim J, Jho EH and Oh ES: Focal adhesion kinase is negatively regulated by phosphorylation at tyrosine 407. J Biol Chem. 282:10398–10404. 2007. View Article : Google Scholar : PubMed/NCBI
22	Jeon J, Lee H, Park H, Lee JH, Choi S, Hwang J, Han IO and Oh ES: Phosphorylation of focal adhesion kinase at Tyrosine 407 negatively regulates Ras transformation of fibroblasts. Biochem Biophys Res Commun. 364:1062–1066. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lie PP, Mruk DD, Mok KW, Su L, Lee WM and Cheng CY: Focal adhesion kinase-Tyr407 and -Tyr397 exhibit antagonistic effects on blood-testis barrier dynamics in the rat. Proc Natl Acad Sci USA. 109:12562–12567. 2012. View Article : Google Scholar : PubMed/NCBI
24	Boivin B, Chaudhary F, Dickinson BC, Haque A, Pero SC, Chang CJ and Tonks NK: Receptor protein-tyrosine phosphatase α regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility. J Biol Chem. 288:36926–36935. 2013. View Article : Google Scholar : PubMed/NCBI
25	Humphries JD, Byron A and Humphries MJ: Integrin ligands at a glance. J Cell Sci. 119:3901–3903. 2006. View Article : Google Scholar : PubMed/NCBI
26	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hakomori SI: Structure and function of glycosphingolipids and sphingolipids: Recollections and future trends. Biochim Biophys Acta. 1780:325–346. 2008. View Article : Google Scholar
28	Hakomori SI and Handa K: GM3 and cancer. Glycoconj J. 32:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
29	Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E, Nagaraju GP, et al: FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget. 6:4757–4772. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hartman ZR, Schaller MD and Agazie YM: The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Mol Cancer Res. 11:651–664. 2013. View Article : Google Scholar : PubMed/NCBI
31	Brunton VG, Avizienyte E, Fincham VJ, Serrels B, Metcalf CA III, Sawyer TK and Frame MC: Identification of Src-specific phosphorylation site on focal adhesion kinase: Dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res. 65:1335–1342. 2005. View Article : Google Scholar : PubMed/NCBI
32	Calalb MB, Polte TR and Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: A role for Src family kinases. Mol Cell Biol. 15:954–963. 1995. View Article : Google Scholar : PubMed/NCBI
33	Ciccimaro E, Hevko J and Blair IA: Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/ multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom. 20:3681–3692. 2006. View Article : Google Scholar
34	Frame MC, Patel H, Serrels B, Lietha D and Eck MJ: The FERM domain: Organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 11:802–814. 2010. View Article : Google Scholar : PubMed/NCBI
35	Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD and Eck MJ: Structural basis for the autoinhibition of focal adhesion kinase. Cell. 129:1177–1187. 2007. View Article : Google Scholar : PubMed/NCBI
36	Mitra SK, Hanson DA and Schlaepfer DD: Focal adhesion kinase: In command and control of cell motility. Nat Rev Mol Cell Biol. 6:56–68. 2005. View Article : Google Scholar : PubMed/NCBI
37	Fincham VJ, Unlu M, Brunton VG, Pitts JD, Wyke JA and Frame MC: Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins. J Cell Biol. 135:1551–1564. 1996. View Article : Google Scholar : PubMed/NCBI
38	Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG and Edwards J: Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol. 175:1389–1397. 2009. View Article : Google Scholar : PubMed/NCBI